Therapeutics Stocks Q2 Earnings: Winners, Losers, and Surprises
Update: 2025-10-13
Description
Biotech Boom or Bust? Q2 Earnings Unpacked! Amgen, Biogen, United Therapeutics, and BioMarin reveal surprising revenue jumps, analyst estimate victories, and stock market shockers. Discover which company soared 46% despite missing expectations, and why a 16% revenue surge led to a stock price plunge. We dissect the trends, opportunities, and challenges shaping the future of therapeutics in a volatile market.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
